Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials (Q30913489)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials (English)

1 reference

Europe PubMed Central

15 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

object named as

D Cunningham

5

0 references

author name string

E Van Cutsem

1

1 reference

Europe PubMed Central

15 August 2017

P M Hoff

2

1 reference

Europe PubMed Central

15 August 2017

P Harper

3

1 reference

Europe PubMed Central

15 August 2017

R M Bukowski

4

1 reference

Europe PubMed Central

15 August 2017

P Dufour

6

1 reference

Europe PubMed Central

15 August 2017

U Graeven

7

1 reference

Europe PubMed Central

15 August 2017

J Lokich

8

1 reference

Europe PubMed Central

15 August 2017

S Madajewicz

9

1 reference

Europe PubMed Central

15 August 2017

J A Maroun

10

1 reference

Europe PubMed Central

15 August 2017

J L Marshall

11

1 reference

Europe PubMed Central

15 August 2017

E P Mitchell

12

1 reference

Europe PubMed Central

15 August 2017

G Perez-Manga

13

1 reference

Europe PubMed Central

15 August 2017

P Rougier

14

1 reference

Europe PubMed Central

15 August 2017

W Schmiegel

15

1 reference

Europe PubMed Central

15 August 2017

J Schoelmerich

16

1 reference

Europe PubMed Central

15 August 2017

A Sobrero

17

1 reference

Europe PubMed Central

15 August 2017

R L Schilsky

18

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

15 August 2017

90

1 reference

Europe PubMed Central

15 August 2017

6

1 reference

Europe PubMed Central

15 August 2017

1190-1197

1 reference

Europe PubMed Central

15 August 2017

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Clinical pharmacokinetics of capecitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

21 June 2018

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601676

21 January 2018

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601676

21 January 2018

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601676

21 January 2018

Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601676

21 January 2018

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601676

21 January 2018

Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409640

25 November 2018

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/15026800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate cancer. NCCN clinical practice guidelines in oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601676

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6601676

1 reference

Europe PubMed Central

15 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Springer Nature article ID

10.1038/sj.bjc.6601676

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30913489&oldid=1842868282"